Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis

DOI Web Site Web Site 3 Citations

Journal

  • Lung Cancer

    Lung Cancer 76 (3), 472-477, 2012-06

    Elsevier BV

Citations (3)*help

See more

Report a problem

Back to top